Conflict of interest statement: Conflict of interest statement: The authorsdeclare that there is no conflict of interest.8. Ecancermedicalscience. 2018 Jun 18;12:ed82. doi: 10.3332/ecancer.2018.ed82.eCollection 2018.Propranolol and breast cancer-a work in progress.Pantziarka P(1)(2), Bryan BA(3), Crispino S(1), Dickerson EB(4)(5).Author information: (1)Anticancer Fund, Brussels, 1853 Strombeek-Bever, Belgium.(2)The George Pantziarka TP53 Trust, London, UK.(3)Department of Biomedical Sciences, Texas Tech University Health SciencesCenter, El Paso, Texas, USA.(4)Department of Veterinary Clinical Sciences, University of Minnesota, SaintPaul, Minnesota, USA.(5)Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, USA.The non-selective beta-blocker propranolol is a leading candidate for repurposingas a novel anti-cancer agent. Emerging evidence, including human data, suggeststhat there are multiple mechanisms of action particularly relevant to breastcancer. This editorial reviews a number of recent studies that show it hasanti-metastatic activity that warrants clinical investigation, includinginvestigation as a potential perioperative therapy in breast cancer.DOI: 10.3332/ecancer.2018.ed82 PMCID: PMC6027968PMID: 30034523 